Day: September 1, 2019

September 2019 Editorial Message

Dear Colleagues:  Welcome to the September 2019 issue of The Journal of Clinical and Aesthetic Dermatology. We begin the issue with an article by Sidgiddi et al, which reports the results of two clinical studies: one that assessed the pharmacokinetic (PK) properties of tazarotene and tazarotenic acid in DFD-03 lotion (a 1-minute, short-contact formulation for


Bioavailability, Pharmacokinetics, and Transepidermal Water Loss of Short-Contact Tazarotene Lotion 0.1% Versus Tazarotene (Tazorac®) Cream 0.1%

by Srinivas Sidgiddi, MD; Kent Allenby, MD; Franklin Okumu, PhD; and Anirudh Gautam, MPharm Drs. Sidgiddi, Allenby, and Okumu are with Promius Pharma in Princeton, New Jersey. Mr. Gautam is with Dr. Reddy’s Laboratories SA in Basel, Switzerland. FUNDING: This study was funded and sponsored by Dr. Reddy’s Laboratories (DRL #841). DISCLOSURES: Dr. Sidgiddi, MD


Topical 15% Zinc Oxide Ointment Significantly Reduces the Size of Common Warts After Four Weeks: A Randomized, Triple-blinded, Placebo-controlled Trial

by Chankiat Songsantiphap, MD, and Pravit Asawanonda, MD, DSc Drs. Songsantiphap and Asawanonda are with the Division of Dermatology in the Department of Medicine at Chulalongkorn University in Bangkok, Thailand.  ABSTRACT: Background. There are limited number of topical agents for the treatment of common warts. Few reports show efficacy of zinc oxide for such indication. Objectives. We